HGH / Somatropin · Research guide

CJC-1295 (with DAC) peptide: HGH / Somatropin research guide

Catalogue reference · Laboratory research only

Not medical advice. CJC-1295 (with DAC) is sold for research. This guide does not recommend dosing, diagnosis, or therapy.

CJC-1295 (with DAC) is listed in our catalogue under “HGH / Somatropin.” In scientific publications it is discussed in technical language; this page translates the general themes into everyday wording while staying faithful to research-only framing.

Plain-language snapshot

One-paragraph overview from our research datasheet—still scientific, but faster to read than the full mechanism list below.

CJC-1295 DAC — long-acting GHRH analogue with maleimidopropionic acid Drug Affinity Complex enabling covalent albumin binding and 6–8 day half-life.

What shows up in scientific writing (general background)

Many readers want context before diving into pathways. The list below summarises what researchers and reviewers discuss—cells, animals, and (for some drug-class molecules) formal clinical trials. It is not a promise of results for any individual.

“Reported” means described in the literature, not recommended for personal use. Our peptides are for laboratory research only.

Typical study contexts & reported directions

Pituitary GH release patterns, receptor signalling, and metabolic readouts in compliant animal research.
Comparisons between secretagogues and exogenous GH in model organisms, focusing on endocrine biology.
Peer-reviewed preclinical work sometimes describes experiments that track whether covalent albumin bioconjugation via MPA-Cys34 bond extends half-life to 5.8–8.1 days
Peer-reviewed preclinical work sometimes describes experiments that track whether tetrasubstituted GHRH(1-29) backbone confers complete DPP-IV protease resistance
Peer-reviewed preclinical work sometimes describes experiments that track whether produces sustained dose-dependent GH elevation of 2–10-fold for 6+ days per injection
Peer-reviewed preclinical work sometimes describes experiments that track whether elevates IGF-1 levels 1.5–3-fold with accumulative effect over 9–28 days

Why HGH / Somatropin research discusses this compound

Growth-hormone axis peptides are researched for how they signal through the GH/IGF pathway in animals and cells. Studies focus on endocrine biology and metabolism, not on prescribing or outcomes in people.

Themes from preclinical literature (technical)

Below are mechanistic bullet points as they appear in our product reference material -useful for researchers comparing pathways. They are not simplified health claims.

Covalent albumin bioconjugation via MPA-Cys34 bond extends half-life to 5.8–8.1 days
Tetrasubstituted GHRH(1-29) backbone confers complete DPP-IV protease resistance
Produces sustained dose-dependent GH elevation of 2–10-fold for 6+ days per injection
Elevates IGF-1 levels 1.5–3-fold with accumulative effect over 9–28 days
Maintains GHRH receptor-mediated pulsatile GH release pattern preserving somatostatin feedback
Approximately 700-fold half-life extension versus native GHRH enabling weekly dosing protocols

Typical handling notes (from our datasheet)

Storage: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. ~5% degradation per year refrigerated. - see our storage guide for best practices on temperature, light, and shelf life.

Typical research dosing discussion (literature-style): 1–2 mg subcutaneously · Once or twice weekly due to extended 6–8 day half-life · Terminal t½ = 5.8–8.1 days; albumin bioconjugation occurs within 15 min post-injection; GH elevation persists ≥6 days; IGF-1 elevation persists 9–11 days after single dose; steady-state IGF-1 with repeated dosing at 28 days. No-DAC variant has ~30 min half-life for comparison.

For preparation, follow the step-by-step reconstitution guide and use the reconstitution calculator to confirm draw volumes. Review subcutaneous injection basics for technique, and always verify batch purity by reading the COA.

Frequently asked questions

What is CJC-1295 (with DAC) in plain language?
CJC-1295 (with DAC) is a research peptide we catalogue under “HGH / Somatropin.” This article explains how scientists discuss it in published literature and what study types usually appear—not as a consumer product claim.

Does this page give medical advice or dosing instructions for CJC-1295 (with DAC)?
No. Content is for laboratory and research literacy only. It does not diagnose, treat, or prevent disease, and is not a dosing guide.

Where can I see purity, variants, and pricing for CJC-1295 (with DAC)?
Use the “View product” button to open the canonical shop listing for CJC-1295 (with DAC), where specifications and research SKU details are shown.

What about online case reports, before-and-after stories, or forum “logs” for CJC-1295 (with DAC)?
Those sources are not peer-reviewed evidence. This guide focuses on preclinical literature and, where relevant, formal clinical trial programmes for drug-class molecules. Anecdotes may be interesting culturally; they are not a safe basis for dosing or medical decisions.

Need vial specs & pricing?

Open the shop listing for variants, purity notes, and research SKU details.

View product

Also known as: CJC-1295 with DAC, DAC:GRF, Drug Affinity Complex GRF, CJC-1295 DAC, Modified GRF 1-29 with DAC, ConjuChem GRF